Publications by authors named "K-U Eckardt"

Posttransplant diabetes mellitus (PTDM) and prediabetes represent serious complications after kidney transplantation and are associated with increased cardiovascular morbidity and mortality. We assessed the predictive performance of continuous glucose monitoring (CGM) compared with plasma glucose and hemoglobin A1c in 46 kidney transplant recipients (KTRs) without known preexisting diabetes mellitus. CGM (14-day recording duration) was performed on days 8, 30, 45, 60, 90, and 180 posttransplant.

View Article and Find Full Text PDF

Background: Persons with chronic kidney disease (CKD) are at increased risk of adverse events, early mortality and multimorbidity. A detailed overview of adverse event types and rates from a large CKD cohort under regular nephrological care is missing. We generated an interactive tool to enable exploration of adverse events and their combinations in the prospective, observational German CKD (GCKD) study.

View Article and Find Full Text PDF

Significance Statement: Early identification of patients at risk of renal flares in ANCA vasculitis is crucial. However, current clinical parameters have limitations in predicting renal relapse accurately. This study investigated the use of urinary CD4 + T lymphocytes as a predictive biomarker for renal flares in ANCA vasculitis.

View Article and Find Full Text PDF

Background: Diabetes mellitus (DM) and chronic kidney disease (CKD) are well-known cardiovascular and mortality risk factors. To what extent they act in an additive manner and whether the etiology of CKD modifies the risk is uncertain.

Methods: The multicenter, prospective, observational German Chronic Kidney Disease study comprises 5217 participants (1868 with DM) with a baseline mean estimated glomerular filtration rate of 30-60 mL/min/1.

View Article and Find Full Text PDF
Article Synopsis
  • Vadadustat is being studied as an oral alternative to injectable treatments for anemia in patients on peritoneal dialysis, showing comparable safety and efficacy to darbepoetin alfa in clinical trials.
  • A post hoc analysis of the INNO2VATE trials indicated that for patients on peritoneal dialysis, the rates of major cardiovascular events and changes in hemoglobin levels were similar for both treatments.
  • Adverse events were reported less frequently in the vadadustat group compared to the darbepoetin alfa group, suggesting a potentially safer profile for vadadustat in this population.
View Article and Find Full Text PDF

Current equation-based risk stratification algorithms for kidney failure (KF) may have limited applicability in real world settings, where missing information may impede their computation for a large share of patients, hampering one from taking full advantage of the wealth of information collected in electronic health records. To overcome such limitations, we trained and validated the Prognostic Reasoning System for Chronic Kidney Disease (PROGRES-CKD), a novel algorithm predicting end-stage kidney disease (ESKD). PROGRES-CKD is a naïve Bayes classifier predicting ESKD onset within 6 and 24 months in adult, stage 3-to-5 CKD patients.

View Article and Find Full Text PDF

Aims: In acute heart failure (AHF), changes of venous haemoglobin (Hb) concentrations, haematocrit (Hct), and estimated plasma volume (ePV) have been proposed as surrogates of decongestion. These estimates are based on the theoretical assumptions that changes of Hb concentrations and Hct are driven by the intravascular volume status and that the intravascular Hb pool remains stable. The objective of this study was to assess the relationship of changes of measured plasma volume (mPV) with changes of Hb, Hct, and ePV in AHF.

View Article and Find Full Text PDF
Article Synopsis
  • Vadadustat is a medication that stimulates the production of erythropoietin, helping treat anemia in patients with chronic kidney disease on dialysis.
  • Two large phase 3 trials compared its safety and effectiveness to darbepoetin alfa, focusing on cardiovascular events and hemoglobin levels over time.
  • Results showed similar rates of major adverse cardiovascular events between the two treatments, but vadadustat led to slightly lower increases in hemoglobin levels in both incident and prevalent dialysis-dependent chronic kidney disease patients.
View Article and Find Full Text PDF
Article Synopsis
  • * The study involved two large Phase 3 clinical trials focusing on patients with low hemoglobin levels; the main goal was to assess the safety of vadadustat compared to darbepoetin, specifically looking at major cardiovascular events.
  • * Results showed that vadadustat did not meet the safety benchmark compared to darbepoetin, as indicated by a higher hazard ratio for major adverse cardiovascular events, and there was minimal difference in hemoglobin improvement between the two treatments.
View Article and Find Full Text PDF

Background: Arterial hypertension and its organ sequelae show characteristics of T cell-mediated inflammatory diseases. Experimental anti-inflammatory therapies have been shown to ameliorate hypertensive end-organ damage. Recently, the CANTOS study (Canakinumab Antiinflammatory Thrombosis Outcome Study) targeting interleukin-1β demonstrated that anti-inflammatory therapy reduces cardiovascular risk.

View Article and Find Full Text PDF

In patients with chronic kidney disease, data on blood pressure (BP) pattern and its association with target organ damage, which indicates elevated cardiovascular risk, are sparse. In 305 treated hypertensive chronic kidney disease patients, we assessed BP pattern, left ventricular mass (magnetic resonance imaging), intima-media thickness (ultrasound), 24-hour-pulse wave velocity and 24-hour-central augmentation index (Mobil-O-Graph). Controlled hypertension (normal office and ambulatory BP) was found in 41% and sustained uncontrolled hypertension (elevated office and ambulatory BP) in 30% of patients.

View Article and Find Full Text PDF

We evaluated genetics of hyperuricemia and gout, their interaction with kidney function and medication intake in chronic kidney disease (CKD) patients. Genome-wide association studies (GWAS) of urate and gout were performed in 4941 CKD patients in the German Chronic Kidney Disease (GCKD) study. Effect estimates of 26 known urate-associated population-based single nucleotide polymorphisms (SNPs) were examined.

View Article and Find Full Text PDF

Tuberous-sclerosis-complex (TSC) is associated with a high lifetime risk of severe complications. Clinical manifestations are largely variable and diagnosis is often missed. Sclerotic-bone-lesions (SBL) could represent a potential imaging biomarker for the diagnosis of TSC.

View Article and Find Full Text PDF

Recently we identified hypoxia-inducible protein 2 (HIG2)/hypoxia-inducible lipid droplet-associated (HILPDA) as lipid droplet (LD) protein. Because HILPDA is highly expressed in atherosclerotic plaques, we examined its regulation and function in murine macrophages, compared it to the LD adipose differentiation-related protein (Adrp)/perilipin 2 (Plin2), and investigated its effects on atherogenesis in apolipoprotein E-deficient () mice. -Cre-driven conditional knockout (cKO) did not affect viability, proliferation, and ATP levels in macrophages.

View Article and Find Full Text PDF
Article Synopsis
  • Accurate 24-hour urine collections are essential for estimating individual salt intake, but a single collection may not suffice to detect small differences in intake levels.
  • A study involving 10 men simulating a Mars flight controlled dietary salt intake and measured urinary salt recovery, finding a high recovery rate that indicates a stable sodium balance.
  • Increasing the number of 24-hour urine samples from one to seven significantly improves the accuracy of detecting changes in salt intake, which is important for both patient management and research trials.
View Article and Find Full Text PDF